Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells

Journal of Bone and Mineral Research

Volumn 21, Issue 7, 2006, Pages 993-1002

  Bäckesjö, Carl Magnus ^a   Li, Yan ^a   Lindgren, Urban ^a   Haldosén, Lars Arne ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adipocyte; Mesenchymal stem cells; Osteoblast; Peroxisome proliferator activated receptor ; Sirt1

Indexed keywords

ALIZARIN RED S; FLUORESCENT DYE; ISONICOTINAMIDE; NICOTINAMIDE; NILE RED; OIL RED O; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; POLYPHENOL; PROTEIN SIRT1; RESVERATROL; SIRTUIN; TROGLITAZONE; UNCLASSIFIED DRUG; VON KOSSA;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL COUNT; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IN VITRO STUDY; MESENCHYMAL STEM CELL; MICROSCOPY; MINERALIZATION; MOUSE; MYOBLAST; NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PROADIPOCYTE; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; STAINING; TISSUE ENGINEERING;

ADIPOCYTES; ANIMALS; CALCIFICATION, PHYSIOLOGIC; CELL DIFFERENTIATION; CELL LINE; ENZYME INHIBITORS; MESENCHYMAL STEM CELLS; MICE; NIACINAMIDE; OSTEOBLASTS; OSTEOGENESIS; PPAR GAMMA; RATS; RATS, WISTAR; SIRTUINS; STILBENES;

EID: 33745514431     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060415     Document Type: Article

References (32)

1. Baksh D, Song L, Tuan RS 2004 Adult mesenchymal stem cells: Characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 8:301-316.
2. Oakes BW 2004 Orthopaedic tissue engineering: From laboratory to the clinic. Med J Aust 180(Suppl 5):S35-S38.
3. Meunier P, Aaron J, Edouard C, Vignon G 1971 Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop 80:147-154.
4. Burkhardt R, Kettner G, Bohm W, Schmidmeier M, Schlag R, Frisch B, Mallmann B, Eisenmenger W, Gilg T 1987 Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: A comparative histomorphometric study. Bone 8:157-164.
5. Collas P, Håkelien AM 2003 Teaching cells new tricks. Trends Biotechnol 21:354-361.
6. Nuttall ME, Patton AJ, Olivera DL, Nadeau DP, Gowen M 1998 Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteopenic disorders. J Bone Miner Res 13:371-382.
7. Park SR, Oreffo RO, Triffitt JT 1999 Interconversion potential of cloned human marrow adipocytes in vitro. Bone 24:549-554.
8. Rosen ED, Spiegelman BM 2001 PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37734.
9. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D, Rao MS, Reddy JK 1995 Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: Alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci USA 92:7921-7925.
10. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS 2002 PPARgamma knockdown by engineered transcription factors: Exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev 16:27-32.
11. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H 2004 PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113:846-855.
12. Hihi AK, Michalik L, Wahli W 2002 PPARs: Transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 59:790-798.
13. Johnson TE, Vogel R, Rutledge SJ, Rodan G, Schmidt A 1999 Thiazolidinedione effects on glucocorticoid receptor-mediated gene transcription and differentiation in osteoblastic cells. Endocrinology 140:3245-3254.
14. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL 2002 Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143:2376-2384.
15. Okazaki R, Toriumi M, Fukumoto S, Miyamoto M, Fujita T, Tanaka K, Takeuchi Y 1999 Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140:5060-5065.
16. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401-406.
17. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, Guarente L 2004 Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429:771-776.
18. Porcu M, Chiarugi A 2005 The emerging therapeutic potential of sirtuin-interacting drugs: From cell death to lifespan extension. Trends Pharmacol Sci 26:94-103.
19. Grigoriadis AE, Heersche JN, Aubin JE 1988 Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: Effect of dexamethasone. J Cell Biol 106:2139-2151.
20. Duque G, Macoritto M, Kremer R 2004 1,25(OH)2D3 inhibits bone marrow adipogenesis in senescence accelerated mice (SAM-P/6) by decreasing the expression of peroxisome proliferator-activated receptor gamma 2 (PPARgamma2). Exp Gerontol 39:333-338.
21. Camp HS, Whitton AL, Tafuri SR 1999 PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes. FEBS Lett 447:186-190.
22. Sauve AA, Moir RD, Schramm VL, Willis IM 2005 Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell 17:595-601.
23. Gehm BD, McAndrews JM, Chien PY, Jameson JL 1997 Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94:14138-14143.
24. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, Sun J, Katzenellenbogen BS, Katzenellenbogen JA 2000 Pyrazole ligands: Structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43:4934-4947.
25. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA 2001 Estrogen receptor-beta potency-selective ligands: Structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44:4230-4251.
26. Bouras T, Fu M, Sauve AA, Wang F, Quong AA, Perkins ND, Hay RT, Gu W, Pestell RG 2005 SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem 280:10264-10276.
27. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Hee Park S, Thompson T, Karsenty G, Bradley A, Donehower LA 2002 p53 mutant mice that display early ageing-associated phenotypes. Nature 415:45-53.
28. Knouff C, Auwerx J 2004 Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: Lessons from genetics and pharmacology. Endocr Rev 25:899-918.
29. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, Kadowaki T 1999 PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609.
30. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W 2002 A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628-2644.
31. Diascro DD Jr, Vogel RL, Johnson TE, Witherup KM, Pitzenberger SM, Rutledge SJ, Prescott DJ, Rodan GA, Schmidt A 1998 High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. J Bone Miner Res 13:96-106.
32. Bagchi D, Das DK, Tosaki A, Bagchi M, Kothari SC 2001 Benefits of resveratrol in women's health. Drugs Exp Clin Res 27:233-248.